



Resource impact statement

Resource impact

Published: 30 June 2022

www.nice.org.uk

No significant resource impact is anticipated

NICE has recommended teduglutide as an option for treating short bowel syndrome (SBS) in people 1 year and above. People should be stable following a period of intestinal adaptation after surgery before having teduglutide. Teduglutide is recommended only if the company provides it according to the commercial arrangement (see section 2 of guidance)

We do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year (or approximately £9,000 per 100,000 population, based on a population for England of 56.3 million people).

This is because the population size is small.

Teduglutide has a discount that is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

This technology is commissioned by NHS England. Providers are NHS hospital trusts.